摘要
慢性肾病在中国是常见的多发疾病,但由于其知晓率低,常为患者忽视,严重者可能会发展为尿毒症,给社会和家庭造成极大的隐患。慢性肾病患者根据其病理进程一般可分为5个阶段,在就诊的患者中,经过诊断发现,心血管疾病是其常见的慢性多发病。因此在患者就诊早期对患者进行心血管疾病发病风险评估具有非常重要的现实意义。半乳糖凝集素3(Gal-3),成纤维细胞生长因子23(FGF23)是存在于血清中的临床上常用的生物辅助诊断标记物。本研究通过收集来我院就诊住院的慢性肾病患者的临床资料包括血压、肾小球率过滤、左心室质量、左心室质量分数、射血分数,以及分别检测各患者血清中Gal-3、FGF23的含量,进行相关性分析,以探讨Gal-3、FGF23对慢性肾病患者发生心血管疾病的风险关系。结果发现,在收集到的120例患者中,单因素分析显示Gal-3和FGF23都是心血管疾病发生的独立决定性因素,且随着Gal-3、FGF23含量的升高,患者的心脏和肾脏功能逐渐减弱,且心脏的塑形性也发生明显变化。这提示我们,Gal-3,FGF23可以作为慢性肾病患者发生心血管疾病的风险评估指标应用在临床诊断中,但其潜在的生物机制还需要更深一步的研究。
Chronic kidney disease is a common multiple disease in Chinese, which was often neglected due to its lower awareness. And severe cases may develop into uremia, which caused great hidden danger to society and family. Patients with chronic kidney disease can be generally divided into five stages according to pathological process. As found, cardiovascular disease is the common chronic frequently-occurring disease. So assessing cardiovascular disease risk in early stage was very significant. Galactose lectin 3 and fibroblast growth factor 23 were clinically common biological auxiliary diagnostic markers in the serum. Here clinical data of our hospital patients with chronic kidney disease in hospital was collected, including blood pressure, rate of glomerular filtration, left ventricular mass, left ventricular mass fraction, ejection fraction, content of FGF23 and Gal in serum.Correlation analysis was processed between Gal-3, FGF23 and cardiovascular disease risk in patients with chronic kidney disease. As the results shown, Gal-3 and FGF23 are independent of CVD decisive factor, and as the Gal-3,FGF23 content increasing cardiac and renal function in patients got weak gradually. Additionally, shape of the heart also altered obviously. In conclusion, Gal-3 and FGF23 can be evaluation indexes of cardiovascular disease risk in patients with chronic kidney disease, which can be applied in clinical diagnosis, but its potential biological mechanism need further researches.
作者
郭莉
陈航
马敬哲
杨彦利
常欢
李文艳
董秀茹
李晶
Guo Li;Chen Hang;Ma Jingzhe;Yang Yanli;Chang Huan;Li Wenyan;Dong Xiuru;Li Jing(Affiliated Hospital of Hebei University, Baoding, 071000)
出处
《基因组学与应用生物学》
CAS
CSCD
北大核心
2018年第4期1786-1791,共6页
Genomics and Applied Biology
基金
河北大学附属医院资助